Amphotericin B and Antifungal Stewardship in Somalia: Irrational Use, Misconceptions, and Emerging Challenges

Abstract

This commentary examines the rapidly escalating global health crisis of antimicrobial resistance (AMR). While widespread attention has historically focused on antibacterial resistance, the emergence of antifungal resistance represents an underrecognized and increasingly severe threat, particularly in resource-limited and fragile health systems. Amphotericin B is a critical, last-line antifungal agent essential for treating life-threatening invasive fungal infections, including cryptococcal meningitis and visceral leishmaniasis. However, due to its severe toxicity profile including nephrotoxicity and severe infusion reactions its administration requires stringent clinical oversight. In fragile health systems such as Somalia, weak pharmaceutical regulation and the proliferation of informal medicine markets have facilitated the irrational use of prescription-only medications. Recently, there are growing concerns regarding public misconceptions surrounding injectable medications, including the potential off-label, non-medical use of high-risk antifungals for purported cosmetic or body-enhancing purposes. While these concerns are currently based on anecdotal observations rather than documented epidemiological evidence, inappropriate community access to Amphotericin B poses severe patient safety risks while potentially accelerating antifungal selection pressure. This commentary explores the clinical importance of Amphotericin B, examines the intersection of public misinformation and irrational drug use, and outlines the urgent need for targeted antifungal stewardship (AFS). Furthermore, it provides a practical framework for facility-level priorities, pharmaceutical regulation, pharmacovigilance, and public health communication. Safeguarding critical antifungal agents in low-resource settings requires immediate, coordinated stewardship and regulatory interventions.

Introduction

The global acceleration of antimicrobial resistance (AMR) is one of the most pressing public health challenges of the 21st century.¹ Globally, invasive fungal infections affect millions of people and are responsible for an estimated 1.5 to 2 million deaths annually.² While extensive global health initiatives have rightfully targeted the stewardship of antibacterial agents, the phenomenon of antifungal resistance remains critically underrecognized.³ Recently, the World Health Organization (WHO) published its first-ever Fungal Priority Pathogens List, highlighting the urgent need for heightened surveillance, research, and stewardship to combat drug-resistant fungal infections.⁴ The WHO identified a “critical priority” group comprising Cryptococcus neoformans, Candida auris, Aspergillus fumigatus, and Candida albicans. First-line antifungals typically include azoles (which inhibit ergosterol synthesis), echinocandins (which inhibit cell wall synthesis), and polyenes (which bind to ergosterol). However, increased fungal resistance is rapidly rendering these agents ineffective; for example, widespread azole resistance is now observed in Aspergillus fumigatus, and Candida auris frequently exhibits multi-drug resistance.⁵ As the population of immunosuppressed individuals grows globally, invasive fungal infections have become a leading cause of morbidity and mortality, necessitating the preservation of effective antifungal therapies.⁶

Despite the availability of newer agents, Amphotericin B continues to be an essential, life-saving antifungal due to its uniquely broad spectrum of activity, rapid fungicidal action, and utility against infections that have developed resistance to azoles and echinocandins. In low- and middle-income countries (LMICs), the containment of AMR is frequently compromised by systemic challenges, including weak pharmaceutical regulation, fragmented supply chains, and limited diagnostic infrastructure.⁷ In such environments, self-medication and the irrational use of antimicrobials are widespread. Furthermore, public misinformation regarding the efficacy and utility of prescription medicines frequently leads to inappropriate utilization. In fragile health systems, where enforcement of prescription-only medicine (POM) policies is inconsistent, the informal circulation of potent pharmacological agents presents a severe risk to public health.⁸

Somalia faces unique and multifaceted challenges in mitigating AMR. Prolonged systemic fragility has heavily impacted the regulatory oversight of pharmaceutical dispensing, leaving communities vulnerable to the unregulated distribution of high-risk medications.⁹ Although Amphotericin B is theoretically classified as a prescription-only medicine (POM) in Somalia, weak regulatory enforcement means the drug can often be accessed through informal markets and unregulated retail pharmacies. Current literature highlights significant gaps in infection prevention and control (IPC) and antimicrobial stewardship (AMS) within Somali healthcare facilities.^10,11 Within this context, the irrational use of critical antifungal agents, such as Amphotericin B, represents an emerging public health concern. It is important to note early in this discussion that reports regarding the non-medical or cosmetic use of Amphotericin B in Somalia stem from emerging observational concerns rather than documented epidemiological evidence; thus, highlighting these issues serves to generate hypotheses and guide future surveillance. This commentary discusses the clinical utility and high-risk profile of Amphotericin B, explores the dangers of public misconceptions driving non-medical use, and delineates actionable priorities for establishing antifungal stewardship in Somalia.

Understanding Amphotericin B: A Lifesaving but High-Risk Antifungal

Amphotericin B is a polyene antifungal that exerts its fungicidal activity by binding to ergosterol, the principal sterol in the fungal cell membrane. This binding leads to the formation of pores, altering membrane permeability and ultimately causing cell death.^4,9 Due to its broad spectrum of activity, Amphotericin B remains a cornerstone of therapy for severe, life-threatening systemic fungal infections. Its primary clinical indications include the treatment of cryptococcal meningitis, progressive disseminated histoplasmosis, invasive candidiasis, invasive aspergillosis, and visceral leishmaniasis.¹²

Despite its life-saving potential, Amphotericin B is colloquially referred to in clinical settings as “amphoterrible” due to its profound toxicity profile. The administration of conventional Amphotericin B deoxycholate is frequently associated with severe adverse effects. Foremost among these is nephrotoxicity; the drug causes direct vasoconstriction of the afferent arterioles, leading to reduced glomerular filtration rate and direct tubular damage.¹³ Consequently, patients frequently experience significant electrolyte disturbances, particularly severe hypokalemia and hypomagnesemia, which can precipitate fatal cardiac arrhythmias.¹⁴

Furthermore, the intravenous administration of Amphotericin B is commonly associated with acute infusion-related reactions—characterized by fever, rigors, chills, hypotension, and hypoxia.¹⁵ Due to these significant hazards, the clinical administration of Amphotericin B strictly necessitates a controlled hospital environment. It requires intensive monitoring of renal function, serum electrolytes, and vital signs, alongside the proactive administration of intravenous fluids and premedication to mitigate infusion reactions.¹⁶ Given this narrow therapeutic index, Amphotericin B is classified as a high-risk medication whose availability must be restricted entirely to specialized clinical settings.

Public Misconceptions and Risks of Irrational Use

In resource-limited settings characterized by pluralistic healthcare-seeking behaviors, informal medicine circulation poses a substantial barrier to rational drug use. The availability of POMs without appropriate clinical oversight allows for the misuse of highly potent antimicrobials. Beyond traditional self-medication for suspected infectious ailments, there are growing concerns regarding the utilization of pharmaceutical agents for entirely non-medical applications.

In various global contexts, misconceptions surrounding the efficacy of injectable medications have led to the inappropriate community use of drugs for cosmetic or body-enhancing alterations, such as weight gain or skin modification. Currently, there is no direct published epidemiological evidence documenting the cosmetic misuse of Amphotericin B in Somalia. However, anecdotal observations from healthcare practitioners and emerging trends within informal drug distribution networks suggest that highly potent injectables may occasionally be vulnerable to such irrational applications due to deep-seated public misunderstandings of their pharmacological effects.

It must be stated unequivocally: there is no scientific evidence supporting the use of Amphotericin B or any systemic antifungal for cosmetic, nutritional, or body-altering purposes. The irrational deployment of such a highly toxic agent in healthy individuals poses extreme patient safety risks. Administering an agent with high nephrotoxic and arrhythmogenic potential outside of a monitored clinical environment can lead to irreversible kidney damage, acute cardiovascular events, and death.¹⁷

In addition to its direct toxicities, the concurrent administration of Amphotericin B with other medications poses severe risks due to adverse drug interactions. Because Amphotericin B is inherently nephrotoxic, combining it with other nephrotoxic drugs such as aminoglycosides, vancomycin, or certain diuretics exponentially increases the risk of acute kidney injury. Furthermore, the profound hypokalemia induced by Amphotericin B can potentiate the toxicity of digoxin, leading to fatal cardiac arrhythmias. These severe drug-drug interactions underscore why this medication must only be administered under strict clinical supervision.

Furthermore, the irrational use of antifungals has severe stewardship implications. Exposure of environmental and commensal fungal flora to sub-therapeutic or inappropriate antifungal concentrations drives selection pressure, potentially accelerating the emergence of resistant fungal strains.¹⁸ In the absence of robust pharmaceutical regulation, the unregulated access to such high-risk injectables jeopardizes both individual lives and broader public health security.

Antifungal Stewardship in Resource-Limited Settings

Antifungal stewardship (AFS) is an essential, albeit frequently overlooked, component of broader AMS programs.¹⁹ The primary objective of AFS is to ensure the optimal utilization of antifungal agents including the correct indication, selection, dosing, route of administration, and duration of therapy while minimizing toxicity and mitigating the emergence of resistance.²⁰

In LMICs, the implementation of AFS faces distinct operational hurdles.²¹ Effective AFS traditionally relies on robust mycology laboratory capacity for the timely identification of fungal pathogens and the determination of susceptibility profiles. Where diagnostic infrastructure is limited, reliance on empiric therapy increases, necessitating carefully calibrated local treatment guidelines.²² Rational prescribing must be championed by multidisciplinary teams, including infectious disease clinicians, clinical pharmacists, and microbiologists.²³

Pharmacovigilance is another critical pillar of AFS, particularly concerning highly toxic medications. Routine monitoring and reporting of adverse drug events (ADEs) associated with antifungals ensure patient safety and inform institutional guidelines. Within LMICs, integrating AFS into existing AMS initiatives leveraging the WHO AWaRe (Access, Watch, Reserve) framework principles adapted for antifungals,¹⁴ can optimize resource utilization. Additionally, regular healthcare worker education regarding the toxicological profiles of last-line agents is vital to ensure that prescribing and dispensing practices remain evidence-based and tightly controlled.²⁴

Somalia and Similar Fragile Health Systems

The healthcare system in Somalia is navigating a period of gradual recovery and restructuring following decades of instability. Despite ongoing institutional rebuilding, pharmaceutical regulation remains critically weak, facilitating a landscape where access to medicines often occurs without adequate clinical or regulatory oversight. Retail pharmacies and unregulated drug vendors frequently operate as primary care providers, leading to the routine over-the-counter dispensing of antibiotics and other POMs.²⁵

Diagnostic limitations further complicate clinical practice in Somalia. The scarcity of advanced microbiological and mycological diagnostics means that clinicians are frequently forced to rely on syndromic management. Additionally, while recent studies have documented varying levels of knowledge, attitudes, and behaviors regarding AMS among physicians in Mogadishu, structural barriers often impede the translation of knowledge into rational prescribing practices.²⁶

The Somalia National Action Plan (NAP) on Combating Antimicrobial Resistance emphasizes the necessity of optimizing antimicrobial use and strengthening knowledge and evidence through surveillance.²⁷ However, current policy implementations largely prioritize antibacterial agents. The unique threat posed by unregulated antifungal distribution compounded by potential public misinformation regarding injectable therapeutics highlights a distinct policy gap. Effectively addressing this requires coordinated efforts from the Ministry of Health, academic institutions, clinical leaders, and community health advocates to establish functional pharmacovigilance and stringent dispensing regulations.

Practical Public Health Recommendations

To mitigate the risks associated with the irrational use of Amphotericin B and to proactively establish antifungal stewardship in Somalia, a multi-tiered approach is required (See Table 1 for a strategic framework).

Table 1.

Strategic Framework for Antifungal Stewardship and Rational Use in Fragile Health Systems

Domain	Recommended Action	Primary Stakeholders	Expected Outcome
1. Pharmaceutical Regulation	Strictly enforce Prescription-Only Medicine (POM) status for all systemic antifungals; restrict Amphotericin B dispensing exclusively to hospital pharmacies.	Ministry of Health, National Drug Authorities, Pharmacy Boards	Prevention of community access to high-risk, toxic injectables.
2. Antifungal Stewardship (AFS)	Integrate AFS protocols into existing AMS programs; develop national guidelines for empiric and targeted antifungal therapy.	Hospital AMS Committees, Infectious Disease Clinicians, Clinical Pharmacists	Rationalized prescribing practices and reduced selective pressure for resistance.
3. Pharmacovigilance	Establish facility-level adverse drug event (ADE) reporting systems specifically tracking nephrotoxicity and infusion reactions associated with antifungals.	Clinical Pharmacists, Nursing Staff, Quality Assurance Teams	Enhanced patient safety and real-time monitoring of drug toxicity.
4. Diagnostic Capacity	Invest in basic and intermediate mycology diagnostic infrastructure (eg, fungal culturing, cryptococcal antigen lateral flow assays) to guide targeted therapy.	Hospital Administration, Laboratory Technicians, International Donors	Reduction in unnecessary empiric antifungal use; improved clinical outcomes.
5. Public Awareness	Launch targeted community health communication campaigns debunking misconceptions regarding the non-medical/cosmetic use of injectable medicines.	Public Health Officials, Community Leaders, Media Outlets	Reduction in irrational healthcare-seeking behavior and drug misuse.
6. Professional Education	Conduct continuous medical education (CME) for doctors and pharmacists on the severe toxicity profile of Amphotericin B and the principles of AFS.	Medical Universities, Professional Associations, Hospital Leadership	Improved clinical knowledge translating to cautious and evidence-based medicine dispensing.

Limitations of the Commentary

While this commentary draws upon established pharmacological data, global AMR principles, and the recognized systemic vulnerabilities of fragile health systems, certain limitations must be acknowledged. Primarily, there is a lack of large-scale, empirical epidemiological data quantifying the precise prevalence of Amphotericin B misuse or the extent of antifungal resistance in Somalia. The concerns discussed herein regarding non-medical and cosmetic applications of injectables are derived from observational insights, informal sector trends, and parallels with other misused pharmaceuticals in similar LMIC contexts. Therefore, these observations highlight a critical knowledge gap rather than a quantified prevalence rate.

Research Agenda

To transition from observational concern to evidence-based policy, a robust research agenda is urgently needed. Future studies in Somalia and similar contexts should prioritize:

1. Surveillance of Antifungal Use: Conducting point-prevalence surveys (PPS) in both clinical settings and community pharmacies to quantify the dispensing patterns of systemic antifungals.

2. Qualitative Behavioral Research: Investigating the socio-cultural drivers and public misconceptions surrounding the use of injectable medications, specifically exploring off-label or non-medical use.

3. Stewardship Implementation Studies: Evaluating the feasibility, barriers, and clinical outcomes of integrating AFS protocols within existing AMS frameworks in resource-limited hospitals.

4. Resistance Monitoring: Establishing baseline epidemiological data on the prevalence of antifungal resistance among clinical isolates (eg, Candida and Aspergillus species) in Somali tertiary care centers.

5. Pharmacovigilance Audits: Assessing the incidence and management of Amphotericin B-induced nephrotoxicity in clinical settings to inform localized safety guidelines.

Conclusion

The emergence of antifungal resistance represents a critical yet under-addressed component of the global AMR crisis. Amphotericin B remains an indispensable agent for the treatment of severe invasive fungal infections; however, its profound toxicity mandates strict clinical oversight. In fragile health systems such as Somalia, weak regulatory frameworks and widespread public misconceptions regarding injectable therapies create a highly hazardous environment prone to the irrational and potentially non-medical use of such agents.

It is vital to acknowledge that concerns regarding the non-medical or cosmetic use of Amphotericin B are currently based on observational insights rather than robust epidemiological data. Consequently, a paramount priority must be the initiation of formal surveillance and epidemiological research to accurately quantify the extent of antifungal misuse in Somalia. Safeguarding these last-line therapies requires urgent, multi-sectoral intervention. Enhancing pharmaceutical regulation, integrating antifungal stewardship into national AMR action plans, expanding diagnostic capacities, and launching targeted public awareness campaigns are essential steps. By prioritizing these interventions, policymakers and clinical leaders can mitigate the risks of severe drug toxicity, curb the emergence of antifungal resistance, and preserve the efficacy of essential life-saving medications for future generations.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Abbreviations

ADE, Adverse Drug Event; AFS, Antifungal Stewardship; AMR, Antimicrobial Resistance; AMS, Antimicrobial Stewardship; IPC, Infection Prevention and Control; LMICs, Low- and Middle-Income Countries; NAP, National Action Plan; POM, Prescription-Only Medicine; WHO, World Health Organization.

Data Sharing Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this commentary.

Ethics Approval and Informed Consent

As this is a commentary article that does not involve primary data collection from human or animal subjects, ethics approval and informed consent were not required.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The author reports no conflicts of interest in this work.